Literature Highlights - August 2023
AURORA 2, Voclosporin, Lupus Nephritis, BLISS-LN, Belimumab
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
AURORA 2, Voclosporin, Lupus Nephritis, BLISS-LN, Belimumab
Lancet Rheumatol. 2022. Epub ahead of print. doi: 10.1016/S2665-9913(22)00304-6
Lupus low disease activity state (LLDAS) significantly reduced the risk of mortality in patients with SLE.
Kidney Int 2019;95:219–31
Calcineurin inhibitors have the potential to increase the likelihood of complete renal remission (CRR) when added to standard-of-care induction therapy for LN.